EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Targeted liquid chromatography–tandem mass spectrometry profiling of arginine and histidine derivatives in chronic migraine: Discriminatory performance and changes after onabotulinumtoxinA therapy

Seyma Dumur iD, Kadidiatou Diarra, Joudy Sewidan, Julie Jalila Kalmoni, Demet Aygun, Dildar Konukoglu, Hafize Uzun

Headache: The Journal of Head and Face Pain · 2026

DOI: 10.1111/head.70179 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, 2026. Verfasst von Seyma Dumur und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry, Faculty of Medicine, Istanbul Atlas University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Migraine Disorders, Histidine, Arginine. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study was conducted to characterize plasma arginine, histidine, 1‐methylhistidine, and 3‐methylhistidine in chronic migraine and to evaluate their discriminatory ability and association with early clinical response to onabotulinumtoxinA (BoNT‐A).

Background

Alterations in nitric oxide‐ and histamine‐related metabolic pathways may contribute to chronic migraine biology and may provide circulating biomarkers for disease stratification and treatment monitoring. Targeted liquid chromatography–tandem mass spectrometry profiling enables precise quantification of candidate amino acids and derivatives implicated in these pathways.

Methods

This retrospective secondary analysis was conducted as a case–control study with an embedded uncontrolled pre‐post analysis and included 30 adults with chronic migraine receiving BoNT‐A and 30 age‐ and sex‐matched healthy controls from Istanbul Atlas University Hospital, based on clinical and laboratory data collected between May 15, 2023, and December 15, 2024. Plasma arginine, histidine, 1‐methylhistidine, and 3‐methylhistidine were quantified by liquid chromatography–tandem mass spectrometry. In the chronic migraine group, pain intensity (visual analog scale [VAS]) and monthly migraine attack frequency were assessed at baseline and 1 month after BoNT‐A. Between‐group comparisons and within‐subject pre‐post comparisons were performed, and exploratory analyses evaluated relationships between metabolite levels and clinical outcomes.

Results

At baseline, compared with controls, patients with chronic migraine had higher plasma arginine (57.3 ± 13.8 vs. 35.9 ± 10.1 μmol/L; p < 0.001) and 3‐methylhistidine (1.0 ± 0.4 vs. 0.7 ± 0.4 μmol/L; p = 0.004), and lower histidine (51.7 ± 10.2 vs. 61.5 ± 6.8 μmol/L; p < 0.001); 1‐methylhistidine did not differ significantly ( p = 0.217). After BoNT‐A, median VAS decreased from 8.0 (7.0–9.0) to 2.0 (0.0–3.0) ( p < 0.001) and median monthly migraine attack frequency decreased from 11.0 (6.0–14.8) to 1.0 (0.0–1.8) ( p < 0.001). Histidine increased from 54.10 μmol/L (45.27–59.81) to 60.23 μmol/L (57.87–64.45); p = 0.003) whereas 3‐methylhistidine decreased from 0.85 μmol/L (0.69–1.23) to 0.66 μmol/L (0.59–0.83); p < 0.001). 1‐Methylhistidine did not change significantly, with median values of 5.39 μmol/L (3.41–14.28) at baseline and 6.84 μmol/L (3.36–15.33) at month 1 ( p = 0.658). Arginine also did not change significantly with median values of 56.74 μmol/L (46.56–65.95) at baseline and 52.83 μmol/L (44.22–66.30) at month 1 ( p = 0.248). Change in histidine was not associated with ΔVAS, and exploratory regression analyses did not identify a robust independent association between baseline variables and pain reduction. In receiver operating characteristic analyses, histidine (area under the curve [AUC] = 0.79) and 3‐methylhistidine (AUC = 0.71) showed moderate discrimination, whereas arginine showed higher apparent discrimination (AUC = 0.91). An exploratory combined biomarker model incorporating arginine, histidine, and 3‐methylhistidine showed higher apparent discrimination (AUC = 0.94; leave‐one‐out cross‐validated AUC = 0.92).

Conclusion

Chronic migraine is associated with an arginine‐histidine metabolic signature characterized by elevated arginine and 3‐methylhistidine and reduced histidine. Early response to BoNT‐A is accompanied by substantial clinical improvement and selective modulation of histidine‐related metabolites. Histidine and 3‐methylhistidine may have value as candidate biomarkers within a broader chronic migraine stratification framework, warranting validation in larger prospective cohorts. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type AMigraine DisordersHistidineArginineHumansTandem Mass SpectrometryFemaleRetrospective StudiesCase-Control StudiesMaleAdultLiquid Chromatography-Mass SpectrometryBiomarkersMiddle AgedMethylhistidinesChronic DiseaseChromatography, Liquid

Stichwörter der Autor:innen

3‐methylhistidineLiquid chromatography–tandem mass spectrometryargininebiomarkerschronic migraineonabotulinumtoxinA

Substanzen

Botulinum Toxins, Type AHistidineArginineBiomarkersonabotulinum toxin AMethylhistidines3-methylhistidine1-methylhistidine

Autor:innen und Institutionen

  • Department of Medical Biochemistry, Faculty of Medicine, Istanbul Atlas University, Istanbul, Turkey.
  • Lincoln College, University of Oxford, Oxford, UK.
  • Department of Chemistry, Imperial College London, London, UK.
  • Department of Neurology, Faculty of Medicine, Istanbul Atlas University, Istanbul, Turkey.
  • Department of Medical Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.

ORCID-Profile: Seyma Dumur

Zitieren

APA

Dumur, S., Diarra, K., Sewidan, J., Kalmoni, J. J., Aygun, D., Konukoglu, D., & Uzun, H. (2026). Targeted liquid chromatography–tandem mass spectrometry profiling of arginine and histidine derivatives in chronic migraine: Discriminatory performance and changes after onabotulinumtoxinA therapy. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.70179

Vancouver

Dumur S, Diarra K, Sewidan J, Kalmoni JJ, Aygun D, Konukoglu D, et al. Targeted liquid chromatography–tandem mass spectrometry profiling of arginine and histidine derivatives in chronic migraine: Discriminatory performance and changes after onabotulinumtoxinA therapy. Headache: The Journal of Head and Face Pain. 2026. doi:10.1111/head.70179

BibTeX
@article{Dumur2026,
  author = {Dumur, Seyma and Diarra, Kadidiatou and Sewidan, Joudy and Kalmoni, Julie Jalila and Aygun, Demet and Konukoglu, Dildar and Uzun, Hafize},
  title = {Targeted liquid chromatography–tandem mass spectrometry profiling of arginine and histidine derivatives in chronic migraine: Discriminatory performance and changes after onabotulinumtoxinA therapy},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  doi = {10.1111/head.70179}
}
Kostenlos starten →